Evaxion Biotech (NASDAQ:EVAX) is flying high today as the company’s personalized cancer therapy EVX-01 reached an important milestone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EVAX has now enrolled the first patient in the global Phase 2b trial of EVX-01which is being developed for the treatment of melanoma.
The trial is evaluating the efficacy and safety of the therapy in adults with metastatic melanoma.
Read full Disclosure